Navigation Links
Nemours Center for Childhood Cancer Research Team at the Alfred I. duPont Hospital for Children Identifies the Function of a Biomarker Present in Prostate Cancer Cells: New Insight into Therapeutic Benefit for Patients with Advanced Prostate Cancer
Date:7/17/2008

WILMINGTON, Del., July 17 /PRNewswire/ -- The research team at the Nemours Center for Childhood Cancer Research (NCCCR), a newly established division of Nemours Biomedical Research at the Alfred I. duPont Hospital for Children has discovered that the biomarker called prostate specific membrane antigen (PSMA), abundantly present in cancer cells of patients with advanced prostate cancer, has a contributory role in the progression of cancer to an aggressive disease. A biomarker is any biomolecule that is associated with a particular pathological or physiological state of cells and may be used to diagnose and treat a disease or monitor response to therapy.

The discovery, titled "Prostate specific membrane antigen associates with anaphase promoting complex and induces chromosomal instability," is outlined in the July issue of Molecular Cancer Therapeutics, an American Association for Cancer Research journal and provides new insights into therapeutic benefit for patients with advanced prostate cancer.

The research was conducted by Dr. Ayyappan K. Rajasekaran, the Director of NCCCR, and his research team while they were at the University of California, Los Angeles, and at NCCCR. The abundance of PSMA in prostate cancer cells increases as the cancer progresses into a metastatic and hormone-independent advanced disease. Dr. Rajasekaran said, "We strongly suspected that PSMA has a potential role in the progression of prostate cancer into an aggressive disease. But how it participates in disease progression was not clear. Now in this study, we identified that PSMA does have an important causative role in prostate cancer progression."

This study was initiated when the researchers found that PSMA was present at the poles of the dividing cells. These poles are complex structures at the opposite ends of the cells that control the separation of chromosomes equally into daughter cells during cell division. "Presence of PSMA at the poles indicated it might have a role in cell division and chromosome segregation, and we continued our quest to understand this potential function of PSMA," said Dr. Rajasekaran.

Human cells have 46 chromosomes. The chromosomes are vehicles that carry the genetic material DNA from generation to generation. These chromosomes are equally divided into daughter cells during cell division. Cells have several checkpoints to ensure that the chromosomes are equally separated during cell division. Anaphase-promoting complex (APC) is one such checkpoint regulatory protein involved in the proper segregation of chromosomes during cell division. This complex monitors the timing of cell division and provides sufficient time for cells to segregate chromosomes equally into daughter cells. Often, cancer cells have more than 46 chromosomes, a condition known as aneuploidy, which is a constant feature of aggressive, advanced, and drug-resistant solid tumors, including prostate cancer.

Rajasekaran and his research team found that PSMA-expressing cells spent less time dividing. They found that PSMA interferes with the function of APC and induces aneuploidy in cancer cells. "When PSMA is present, cells hurried to complete their division prior to having all their chromosomes properly segregated," said Dr. Sigrid A. Rajasekaran, the first author of the study and the head of the Cancer Cell Metabolism Laboratory at NCCCR.

PSMA is present in prostate cancer cells but not in normal cells. Therefore, it is an excellent therapeutic target for prostate cancer. There are several ongoing clinical trials for PSMA-based therapeutic interventions. "Since PSMA expression is higher in metastatic compared to benign cancer cells, anti-PSMA-based therapeutic strategies should target metastatic prostate cancer cells, which will benefit patients with advanced prostate cancer," the study states.

Dr. A. Rajasekaran and his team conducted their research on cell lines and are in the process of translating their findings into human clinical trials, which should be available in two to three years.

This study was primarily supported by the Department of Defense DOD W81XWH-04-1-0113 Idea Development Grant and in part by NIH DK56216.

About the Nemours Center for Childhood Cancer Research

The Nemours Center for Childhood Cancer Research is a newly established research entity of Nemours Biomedical Research at the Alfred I. duPont hospital for children. The NCCCR is located in a fully renovated laboratory space in 1701 Rockland Road, Wilmington, DE. The goal of the center is to evolve into a leader in research focusing on biomarkers for childhood cancers and cancers that affect families. The NCCCR will closely work together with Helen F. Graham Cancer Center, University of Delaware, Center for Translational Research and the Delaware Biotechnology Institute. The Alfred I. duPont Hospital for Children is a division of Nemours, which operates one of the nation's largest health systems devoted to pediatric patient care, teaching, and research. Set on a 300-acre campus near Wilmington, Delaware, the 200-bed duPont Hospital for Children offers all the specialties of pediatric medicine, surgery, and dentistry. Starting with Alfred I. duPont's bequest over 70 years ago, Nemours has grown into a multi-dimensional organization offering personalized clinical and preventive care focused on children. For more information, please visit Nemours.org.


'/>"/>
SOURCE Nemours Center for Childhood Cancer Research
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
6. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
7. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
8. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):